Dr. Carl June from the University of Pennsylvania and Dr. Michel Sadelain from Columbia University receive the first-ever Broermann Medical Innovation Award (BMIA) for their groundbreaking research on CAR-T cell therapy. With an endowment of one million euros, the prize is one of the most highly endowed awards for medical research worldwide. The award ceremony will take place in the Hessian State Chancellery in Wiesbaden, presented by Hesse’s Prime Minister Boris Rhein.

June and Sadelain are being honored for their work on the genetic modification of T cells, which use chimeric antigen receptors (CARs) to recognize and eliminate cancer cells. This therapy achieves high success rates for blood cancers such as leukemia, lymphoma and myeloma and is being tested for other types of cancer. Her research has revolutionized cancer therapy and created new hope for previously incurable patients.

The award winners were selected by a renowned jury of nine high-ranking members of leading scientific institutes in a multi-stage process that ensures the highest scientific standards. Carl June, born in 1953 in Denver, USA, founded the Center for Cellular Immunotherapies at the University of Pennsylvania in 1999. Michel Sadelain, born in Paris in 1960, has been head of the Columbia Initiative in Cell Engineering and Therapy (CICET) in New York since 2024.

The BMIA was launched in 2024 by Dr. Bernard Große Broermann, founder of Asklepios Kliniken, to promote medical innovation. The award continues its vision of improving patient care through investment in cutting-edge technologies and research.

Read Also:

World’s first CAR-T cell therapy for autoimmune neuropathy successfully used in Bochum – MedLabPortal

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.